Insider · CIK 0001992908

Lenz Robert A.

Reports to the SEC for 3 companies · ROCKVILLE, MD

sec.gov

Transactions

Companies

Filings

CIK

0001992908

Forms 4 and 5

Insider transactions

18 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-22	NBPNovaBridge BiosciencesM Exercise/Conversion	Director	MExercise/Conversion	+17.2K sh	—	—	17,218
2026-08-22	NBPNovaBridge Biosciences · Restricted Share UnitsM Exercise/Conversion	Director	MExercise/Conversion	−7,486 sh	—	—	14,974
2026-06-03	LBRXLB PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2026-03-06	LBRXLB PHARMACEUTICALS INC · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2025-02-18	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−5,614 sh	$1.67	−$9,383.24	309,092
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Head of R&D	DDisposition to Issuer	−503K sh	—	—	0
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Head of R&D	DDisposition to Issuer	−100K sh	—	—	0
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Head of R&D	AAward	+503K sh	—	—	502,934
2025-02-13	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Head of R&D	AAward	+100K sh	—	—	100,000
2024-10-10	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−8,260 sh	$15.09	−$125K	314,706
2024-10-09	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−5,563 sh	$15.01	−$83.5K	322,966
2024-09-18	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−10.7K sh	$12.09	−$129K	328,529
2024-09-17	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−30.8K sh	$11.81	−$364K	339,205
2024-09-12	NMRANeumora Therapeutics, Inc.S Sale	Head of R&D	SSale	−32.9K sh	$11.43	−$377K	369,993
2024-02-14	NMRANeumora Therapeutics, Inc.A Award	Head of R&D	AAward	+50K sh	—	—	402,941
2024-02-14	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Head of R&D	AAward	+100K sh	—	—	100,000
2023-09-14	NMRANeumora Therapeutics, Inc.A Award	Head of R&D	AAward	+353K sh	—	—	352,941
2023-09-14	NMRANeumora Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Head of R&D	AAward	+503K sh	—	—	502,934

Recent filings

Accepted (ET)
Aug 254
Lenz Robert A.0001992908-26-000013
SEC(opens sec.gov)
Jun 54
Lenz Robert A.0001992908-26-000011
SEC(opens sec.gov)
Mar 104
Lenz Robert A.0001992908-26-000007
SEC(opens sec.gov)
Feb 204
Lenz Robert A.0001610717-25-000028
SEC(opens sec.gov)
Feb 184
Lenz Robert A.0000950170-25-022322
SEC(opens sec.gov)
Oct 114
Lenz Robert A.0001610717-24-000505
SEC(opens sec.gov)
Sep 194
Lenz Robert A.0001610717-24-000490
SEC(opens sec.gov)
Sep 164
Lenz Robert A.0001610717-24-000478
SEC(opens sec.gov)
Feb 164
Lenz Robert A.0001610717-24-000063
SEC(opens sec.gov)
Sep 184
Lenz Robert A.0001610717-23-000286
SEC(opens sec.gov)

Companies

Address

C/O NOVABRIDGE BIOSCIENCES 2440 RESEARCH BOULEVARD, SUITE 400

ROCKVILLE, MD, 20850